Immuron
Level 1, 39 Leveson Street
North Melbourne
Victoria
3051
Tel: 61-3-9018-4880
Fax: 61-3-9018-4881
Website: http://www.immuron.com/
95 articles about Immuron
-
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
3/7/2024
Immuron Limited is pleased to announce the interim topline results confirming that a single daily dose of Travelan® is effective in prevention of moderate to severe diarrhea following challenge with enterotoxigenic Escherichia coli.
-
Immuron Presentation Australian Biologics Festival 2024
2/21/2024
Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21st February in Melbourne, Australia.
-
Immuron achieves record Travelan® sales
2/13/2024
Immuron Limited is pleased to announce record sales of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.
-
Immuron achieves record half yearly Travelan® sales
1/16/2024
Immuron Limited is pleased to announce record half yearly sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.
-
Immuron Clinical Trials Update
12/22/2023
Immuron Limited is pleased to provide shareholders and the market with an update on the company’s clinical development portfolio.
-
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
12/4/2023
Immuron Limited is pleased to announce that the US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron.
-
Immuron CEO Steven Lydeamore Investor Webinar Presentation
11/13/2023
Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday, 14th November, 2023, 1:00pm AEDT/10:00am AWST.
-
Immuron CEO Steven Lydeamore presented at AusBioInvest
10/30/2023
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer, Steven Lydeamore, presented at AusBioInvest 2023 on Monday, October 30th in the 9.40am – 10.35am session (AEST) at the Park Hyatt, Melbourne, Australia.
-
Immuron Announces Travelan® Clinical Study Cohort 2 commences
10/18/2023
Immuron Limited is pleased to announce the second cohort of 34 participants have commenced the clinical trial to evaluate the efficacy of Travelan® to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli.
-
Immuron achieves record quarterly Travelan® sales
10/11/2023
Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.
-
Immuron achieves record monthly Travelan® sales
9/13/2023
Immuron Limited is pleased to announce record monthly sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.
-
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright - September 11, 2023
9/11/2023
Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th.
-
Immuron to present at the Military Health System Research Symposium
8/14/2023
Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce that it will be presenting at The Military Health System Research Symposium, in Kissimmee, Florida from the 14th to the 17th of August 2023.
-
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
7/25/2023
Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce the first cohort of 30 participants have been enrolled into the clinical trial to evaluate the efficacy of Travelan® to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli.
-
Immuron CEO, Steven Lydeamore to present at Bioshares
7/24/2023
Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the 17th Bioshares Biotech Summit in Hobart, Australia on July 24th.
-
Immuron Business Update - Ateria Health launches Juvia™ in Australia
7/11/2023
Immuron Limited is pleased to announce that Ateria Health Australia Pty Ltd, a subsidiary of Ateria Health Limited, has launched Juvia™ in Australia.
-
Immuron FY23 Sales increase 136% on FY22 Sales
7/5/2023
Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce FY23 sales results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan® and Protectyn®.
-
Immuron Chairman Transition - June 30, 2023
6/30/2023
Immuron Limited, an Australian based and globally integrated biopharmaceutical company, is pleased to announce the transition of Paul Brennan from Non-Executive Director to Chairman, effective July 1, 2023.
-
Immuron Business Update: Letter to Shareholders
6/22/2023
Immuron Limited, an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide the following business update.
-
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
5/8/2023
Immuron Limited is pleased to announce that the US Naval Medical Research Center has received approval from the US Food and Drug Administration to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli developed in collaboration with Immuron.